Prevalencia, factores de riesgo y respuesta al tratamiento de las manifestaciones extraintestinales en pacientes con enfermedad inflamatoria intestinal

Hernández-Tejero, María; Granja Navacerrada, Alicia; Bernal Checa, Pilar; Piqué Becerra, Rubén; Algaba García, Alicia; Guerra Marina, Iván; García-Alonso, Francisco Javier; Syed, Mariano; Bermejo, Fernando.
Rev. esp. enferm. dig ; 109(9): 627-633, sept. 2017. tab
Artículo en Español | IBECS (España) | ID: ibc-165848

Documentos relacionados

  1. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.
  2. Weight and BMI Patterns in a Biologicals-Treated IBD Cohort.
  3. Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study.
  4. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database.
  5. Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease.
  6. Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease.
  7. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease.
  8. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
  9. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
  10. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels.